Press Release: Longer-term Novartis Kisqali(R) -3-

NATALEE. Accessed December,

2024. https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumou

rs/esmo-mcbs-scorecards/scorecard-468-1

23. European Society for Medical Oncology. Magnitude of Clinical Benefit

Scale Scorecard. Accessed December 2024.

https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-158-1

24. European Society for Medical Oncology. Magnitude of Clinical Benefit

Scale Scorecard. Accessed December 2024.

https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-9-1

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Central North America

Anja von Treskow +41 79 392 9697 Michael Meo +1 862 274 5414

Anna Schäfers +41 79 801 7267

Switzerland

Satoshi Sugimoto +41 79 619 2035

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Isabella Zinck +41 61 324 7188 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +41 61 324 3809 Jonathan Graham +1 201 602 9921

Imke Kappes +41 61 324 8269 Parag Mahanti +1 973 876 4912

(END) Dow Jones Newswires

December 10, 2024 09:00 ET (14:00 GMT)